Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 8/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488083 | 0.85 | SIGMAR1 (0.52) | SIGMAR1MEN1KMT2ALMNATSHR | |
| SCHEMBL6528779 | 0.83 | SIGMAR1 (0.50) | SIGMAR1MEN1KMT2ALMNATSHR | |
| SCHEMBL10724043 | 0.82 | SIGMAR1 (0.70) | SIGMAR1MEN1KMT2AKCNH2PLA2G2A | |
| SCHEMBL10723980 | 0.82 | SIGMAR1 (0.70) | SIGMAR1MEN1KMT2AKCNH2PLA2G2A | |
| SCHEMBL10722011 | 0.82 | SIGMAR1 (0.70) | SIGMAR1MEN1KMT2AKCNH2PLA2G2A | |
| SCHEMBL8894983 | 0.81 | MEN1 (0.75) | SIGMAR1MEN1KMT2ALMNATSHR | |
| SCHEMBL16980657 | 0.81 | SIGMAR1 (0.72) | SIGMAR1MEN1KMT2AKCNH2PLA2G2A | |
| SCHEMBL5655904 | 0.79 | SMN1; SMN2 (0.57) | MEN1KMT2ALMNATSHRMAPK1 | |
| SCHEMBL6688415 | 0.79 | CNR2 (0.48) | SIGMAR1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL6688413 | 0.79 | CNR2 (0.51) | SIGMAR1MEN1KMT2ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1612868-A | Ethylene derivative and use as phophatidase | YANG JI CHEMICAL COMPANY LTD (KR) | 2005-05-04 | — | — | CN | disclosed |
| US-20050075345-A1 | Novel inhibitor compounds specific of secreted non-pancreatic human a<sb>2</sb>phospholipase of group II | YANG JI CHEMICAL COMPANY LTD. (KR) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075345-A1 | Novel inhibitor compounds specific of secreted non-pancreatic human a<sb>2</sb>phospholipase of group II | AMY2A, PNLIP, IAPP | SIGMAR1 2516/4885MEN1 1731/4885KMT2A 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.